Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05954897 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 20, 2023 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.
Trial Details
NCT Number NCT05954897
Lead Sponsor Guangdong Provincial People's Hospital
Conditions
(from sponsor)		 Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov